

Audit 2025

Contact:

Tumorzentrum Hirslanden Zürich

Witellikerstrasse 40

8032 Zürich

T +41 44 387 96 62

tumorzentrum.hirslanden@hirslanden.ch

open studies

breast cancer

name of study

CAMBRIA-2 study

EKIB study

EXPERT- study (ANZ 1601/ BIG 16-02)

MELODY-study

PROMs

TAXIS-study (SAKK 23/16)

TroFuse-010 study

VISION-study (SAKK 23/18)

target group/ short description

An adjuvant endocrine-based therapy study of camizestran (AZD9833) in ER+/HER2-early breast cancer (CAMBRIA-2).

Analysis of human breast tumor heterogeneity and immune cell infiltrates and their relevance for patient outcome by mass cytometry.

Clinical trial which presents a unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence (molecular luminal A-breast cancer).

A prospective, non-interventional, multicenter cohort study to investigate various imaging-guided techniques for the localization of malignant breast lesions.

Patient reported outcomes after oncoplastic breast conserving surgery.

Tailored AXillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS).

A study of Sacituzumab Tirumotecan as a single agent and in combination with Pembrolizumab versus treatment of physician's choice in participants with HR+/HER2- unresectable locally advanced or metastatic breast cancer.

Vacuum assisted biopsy immediately before surgery as an intra- or pre-operative surrogate for patient response to neoadjuvant chemotherapy for breast cancer (VISION I).

urogenital tumors

PCO study (Prostate Cancer Outcome)

Patient reported outcome measurement of patients with prostate cancer with global uniform patient questionnaire.

gastrointestinal tumors

MRI bladdercancer study	Multiparametric Magnetic Resonance Imaging (MRI) to improve bladder cancer staging and treatment decision-making.
SAKK 08/23 study	Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial".
BERING CRC study	Encorafenib and Cetuximab in patients with metastasized BRAFV600E mutated colorectal cancer: a multi-centric, multi-national, prospective, longitudinal, non-interventional study.
EDIUM study	Patient-reported outcome study for colon cancer patients: Ergebnisqualität bei Darmkrebs: Identifikation von Unterschieden und Massnahmen zur flächendeckenden Qualitätsentwicklung (Quality of Experience in the case of colon cancer: identification of differences and actions to be taken for a comprehensive quality development)
DANTE Study	A randomized, open-label phase II/III study on the efficacy and safety of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the gastroesophageal junction with high immune reactivity.
ESODATA study	International standardized online database für outcomes of the patients receiving evaluation and/ or treatment für esophageal diseases of benign and malignant conditions.
PREFER-study	Endoscopic management of patients with T1bN0M0 esophageal adenocarcinoma.
Quality assurance study for duodenal tumors	Quality assurance study of perioperative morbidity and post-surgical follow up of hepato-duodeno-pancreatic surgery.
Quality assurance study for pancreatic tumors	Quality assurance study of perioperative morbidity and post-surgical follow up of pancreatic surgery.
ROBOT-2 study	Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial.
Tiger study	Distribution of lymph node metastases in esophageal carcinoma.

hematological systemic diseases

Abbvie Valor-Studie	A study to assess change in disease state in adult participants with acute myeloid leukemia (AML) ineligible for intensive chemotherapy in Switzerland and Austria receiving oral Venetoclax tablets (VALOR).
EBMT-Register	Registry for patients that received a haematopoietic stem cell transplantation or CAR T-cell therapy.
PASS study	Observational study including patients treated with CAR-T therapy to assess treatment outcomes and associated complications.

	SAKK 38/23 Liberty study	Liquid Biopsy to diagnose and monitor CNS involvement in High-risk B Cell Non-Hodgkin Lymphoma.
	SAKK EMCL-Registry	The registry of the European Mantle Cell Lymphoma study group - MCL: Disease pattern, treatment algorithms and mechanisms of relapse.
	Treg-cell study	Regulatory T-cells as tumor-promoting cellular partners and potential therapeutic targets in diffuse large B-cell lymphoma.
neuro-oncological tumors	LGG Studie	Prospective observational study on guideline-based therapy in astrocytomas and oligodendrogliomas, WHO grade 2, with IDH1/2 mutation.
	Sinonasale QoL Studie	Prospective observational study to evaluate the nasal quality of life after endoscopic transnasal surgeries.
multi-organ studies	AGE-1 Studie	Evaluation of forensic methods for age estimation of patient with cancer and a control group.
	Roche GLYCART Studie	Ex vivo modeling of fresh tumor tissue.